Skip to main content

Clinical trial ADRIATIC

A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (D933QC00001 - ADRIATIC)

Organ Poumon
Trial status Trial open for recruitment
Trial type
Interventionnal with IMP
Phase Trial phase 3
Academic trial Non
Sponsor AstraZeneca
EudraCT Identifier 2018-000867-10
Inclusion criteria 4 lines chemotherapy and radiation
Last update